(7.30.16.1) Consumption of purchased electricity (MWh)

15056

(7.30.16.2) Consumption of self-generated electricity (MWh)

1199

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

9018

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

25273.00

Slovakia

(7.30.16.1) Consumption of purchased electricity (MWh)

71

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

33

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

104.00

Slovenia

(7.30.16.1) Consumption of purchased electricity (MWh)

59

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

27

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

86.00

Spain

(7.30.16.1) Consumption of purchased electricity (MWh)

169

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

78

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

247.00

Sweden

(7.30.16.1) Consumption of purchased electricity (MWh)

161

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

74

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

235.00

Switzerland

(7.30.16.1) Consumption of purchased electricity (MWh)

390

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

179

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

569.00

Taiwan, China

(7.30.16.1) Consumption of purchased electricity (MWh)

256

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

118

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

374.00

Thailand

(7.30.16.1) Consumption of purchased electricity (MWh)

94

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

43

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

137.00

Turkey

(7.30.16.1) Consumption of purchased electricity (MWh)

65

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

30

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

95.00

United Arab Emirates

(7.30.16.1) Consumption of purchased electricity (MWh)

63

(7.30.16.2) Consumption of self-generated electricity (MWh)

0

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

29

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

92.00

United Kingdom of Great Britain and Northern Ireland

(7.30.16.1) Consumption of purchased electricity (MWh)

710

(7.30.16.2) Consumption of self-generated electricity (MWh)

10

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

104

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

824.00

United States of America

(7.30.16.1) Consumption of purchased electricity (MWh)

233782

(7.30.16.2) Consumption of self-generated electricity (MWh)

1096

(7.30.16.4) Consumption of purchased heat, steam, and cooling (MWh)

21740

(7.30.16.5) Consumption of self-generated heat, steam, and cooling (MWh)

212997

(7.30.16.6) Total electricity/heat/steam/cooling energy consumption (MWh)

469615.00
[Fixed row]

(7.45) Describe your gross global combined Scope 1 and 2 emissions for the reporting year in metric tons CO2e per unit currency total revenue and provide any additional intensity metrics that are appropriate to your business operations.

Row 1

(7.45.1) Intensity figure

0.00000482

(7.45.2) Metric numerator (Gross global combined Scope 1 and 2 emissions, metric tons CO2e)

161247

(7.45.3) Metric denominator

Select from:
☑ unit total revenue

(7.45.4) Metric denominator: Unit total

33424000000

(7.45.5) Scope 2 figure used

Select from:

☑ Market-based

(7.45.6) % change from previous year

17

(7.45.7) Direction of change

Select from:

☑ Decreased

(7.45.8) Reasons for change

Select all that apply

☑ Change in renewable energy consumption

☑ Other emissions reduction activities

(7.45.9) Please explain

Energy efficiency and innovation projects and continued increase in renewable electricity procurement decreased Scope 1 and Scope 2 emissions.
[Add row]

(7.52) Provide any additional climate-related metrics relevant to your business.

Row 1

(7.52.1) Description

Select from:

☑ Energy usage

(7.52.2) Metric value

94

(7.52.3) Metric numerator

Total Energy from Utilities (1000 GJ)

(7.52.4) Metric denominator (intensity metric only)

Normalized to net Sales ($Billion USD)

(7.52.5) % change from previous year

11

(7.52.6) Direction of change

Select from:
☑ Decreased

(7.52.7) Please explain

Our organization’s total energy normalized to net sales has decreased annually since 2019, the baseline year. In 2024, it decreased 11% compared to 2023.

Row 2

(7.52.1) Description

Select from:
☑ Other, please specify :Carbon Emissions

(7.52.2) Metric value

4

(7.52.3) Metric numerator

Total Carbon from Utilities (1000 MTCO2e)

(7.52.4) Metric denominator (intensity metric only)

Normalized to net sales ($Billion USD)

(7.52.5) % change from previous year

0

(7.52.6) Direction of change

Select from:

☑ No change

(7.52.7) Please explain

Our organization’s total carbon emissions normalized to net sales have decreased or remained unchanged, annually, since 2019, the baseline year. In 2024, it remained constant when compared to 2023.
[Add row]

(7.53) Did you have an emissions target that was active in the reporting year?

Select all that apply

☑ Absolute target

(7.53.1) Provide details of your absolute emissions targets and progress made against those targets.

Row 1

(7.53.1.1) Target reference number

Select from:

☑ Abs 1

(7.53.1.2) Is this a science-based target?

Select from:

☑ Yes, and this target has been approved by the Science Based Targets initiative

(7.53.1.4) Target ambition

Select from:

☑ 1.5°C aligned

(7.53.1.5) Date target was set

08/01/2022

(7.53.1.6) Target coverage

Select from:

☑ Organization-wide

(7.53.1.7) Greenhouse gases covered by target

Select all that apply

☑ Methane (CH4)

☑ Nitrous oxide (N2O)

☑ Carbon dioxide (CO2)

☑ Perfluorocarbons (PFCs)

☑ Hydrofluorocarbons (HFCs)

☑ Sulphur hexafluoride (SF6)

☑ Nitrogen trifluoride (NF3)

(7.53.1.8) Scopes

Select all that apply

☑ Scope 1

☑ Scope 2

☑ Scope 3

(7.53.1.9) Scope 2 accounting method

Select from:

☑ Market-based

(7.53.1.10) Scope 3 categories

Select all that apply

☑ Scope 3, Category 1 – Purchased goods and services

☑ Scope 3, Category 2 – Capital goods

(7.53.1.11) End date of base year

12/31/2019

(7.53.1.12) Base year Scope 1 emissions covered by target (metric tons CO2e)

135954

(7.53.1.13) Base year Scope 2 emissions covered by target (metric tons CO2e)

160360

(7.53.1.14) Base year Scope 3, Category 1: Purchased goods and services emissions covered by target (metric tons CO2e)

2323917

(7.53.1.15) Base year Scope 3, Category 2: Capital goods emissions covered by target (metric tons CO2e)

258132

(7.53.1.31) Base year total Scope 3 emissions covered by target (metric tons CO2e)

2582049.000

(7.53.1.32) Total base year emissions covered by target in all selected Scopes (metric tons CO2e)

2878363.000

(7.53.1.33) Base year Scope 1 emissions covered by target as % of total base year emissions in Scope 1

55

(7.53.1.34) Base year Scope 2 emissions covered by target as % of total base year emissions in Scope 2

55

(7.53.1.35) Base year Scope 3, Category 1: Purchased goods and services emissions covered by target as % of total base year emissions in Scope 3, Category 1: Purchased goods and services (metric tons CO2e)

91

(7.53.1.36) Base year Scope 3, Category 2: Capital goods emissions covered by target as % of total base year emissions in Scope 3, Category 2: Capital goods (metric tons CO2e)

91

(7.53.1.52) Base year total Scope 3 emissions covered by target as % of total base year emissions in Scope 3 (in all Scope 3 categories)

66

(7.53.1.53) Base year emissions covered by target in all selected Scopes as % of total base year emissions in all selected Scopes

100

(7.53.1.54) End date of target

12/31/2027

(7.53.1.55) Targeted reduction from base year (%)

67

(7.53.1.56) Total emissions at end date of target covered by target in all selected Scopes (metric tons CO2e)

949859.790

(7.53.1.57) Scope 1 emissions in reporting year covered by target (metric tons CO2e)

147353

(7.53.1.58) Scope 2 emissions in reporting year covered by target (metric tons CO2e)

13894

(7.53.1.59) Scope 3, Category 1: Purchased goods and services emissions in reporting year covered by target (metric tons CO2e)

945759

(7.53.1.60) Scope 3, Category 2: Capital goods emissions in reporting year covered by target (metric tons CO2e)

220975

(7.53.1.76) Total Scope 3 emissions in reporting year covered by target (metric tons CO2e)

1166734.000

(7.53.1.77) Total emissions in reporting year covered by target in all selected scopes (metric tons CO2e)

1327981.000

(7.53.1.78) Land-related emissions covered by target

Select from:

☑ No, it does not cover any land-related emissions (e.g. non-FLAG SBT)

(7.53.1.79) % of target achieved relative to base year

80.39

(7.53.1.80) Target status in reporting year

Select from:

☑ Underway

(7.53.1.82) Explain target coverage and identify any exclusions

In 2020, we initiated our third multiyear environmental sustainability plan with the aspiration to achieve carbon neutrality (1) in our operations by year-end 2027. Our carbon neutrality goal encompasses 100 percent of Amgen's Scope 1 and Scope 2 (market-based) emissions. This includes emissions from our sales fleet; fugitive emissions from purchased and generated carbon dioxide and refrigerant losses; executive travel; and from energy usage in our operations. For energy use in our operations, we track invoiced energy usage from 87 percent of our worldwide facility space, based on total square feet and calculate emissions from fuel and supplied electricity emission factors. Energy and carbon data for the remaining 13 percent of facility space is estimated based on building energy-intensity factors and country-specific emission factors. This includes leased buildings where we have limited operational control over building infrastructure, including utilities. We also set a commitment with SBTi. (1) Carbon neutrality goal refers to Scope 1 and 2 emissions, inclusive of our acquisition of Horizon Therapeutics plc.

(7.53.1.83) Target objective

Our SBTi commitment is as follows: - Amgen commits to reduce absolute Scope 1 and 2 carbon emissions by 55% from a 2019 baseline year by 2027. - Amgen commits to increase renewable electricity sourcing from 29% to 100% by 2027, and to continually source 100% renewable energy through 2030. - Amgen commits that 73% of its suppliers by spend covering upstream purchased goods and services and capital goods will have science-based targets by 2027. Note that the target for Scope 3 is a supplier engagement commitment, not an absolute carbon reduction target. Our Scope 3 supplier engagement goal for Categories 1 and 2 (Purchased Goods & Services and Capital Goods) covers 67% of our Scope 3 2019 baseline (note this is not an absolute goal). 91% of Scope 3 emissions originate from Categories 1 and 2. 67% of total Scope 3 emissions translates to 73% by spend of Categories 1 and 2.

(7.53.1.84) Plan for achieving target, and progress made to the end of the reporting year

Strategy: Our plan to achieve our 2027 target is to eliminate and reduce energy usage through efficiency, electrification, and the sourcing of renewable energy. We identify and reward projects on a quarterly basis to reduce our environmental footprint (carbon, water, and waste). Special recognition is provided to site teams that reduce or eliminate fossil fuels from our operations. Our Scope 1, 2, and 3 science-based targets were approved by the SBTi in August 2022.

(7.53.1.85) Target derived using a sectoral decarbonization approach

Select from:

☑ No

[Add row]

(7.54) Did you have any other climate-related targets that were active in the reporting year?

Select all that apply

☑ Targets to increase or maintain low-carbon energy consumption or production

☑ Other climate-related targets

(7.54.1) Provide details of your targets to increase or maintain low-carbon energy consumption or production.

Row 1

(7.54.1.1) Target reference number

Select from:

☑ Low 1

(7.54.1.2) Date target was set

08/01/2022

(7.54.1.3) Target coverage

Select from:

☑ Organization-wide

(7.54.1.4) Target type: energy carrier

Select from:

☑ Electricity

(7.54.1.5) Target type: activity

Select from:

☑ Consumption

(7.54.1.6) Target type: energy source

Select from:

☑ Renewable energy source(s) only

(7.54.1.7) End date of base year

12/31/2019

(7.54.1.8) Consumption or production of selected energy carrier in base year (MWh)

480833

(7.54.1.9) % share of low-carbon or renewable energy in base year

29

(7.54.1.10) End date of target

12/31/2027

(7.54.1.11) % share of low-carbon or renewable energy at end date of target

100

(7.54.1.12) % share of low-carbon or renewable energy in reporting year

90

(7.54.1.13) % of target achieved relative to base year

85.92

(7.54.1.14) Target status in reporting year

Select from:

☑ Underway

(7.54.1.16) Is this target part of an emissions target?

Yes, this target forms part of our SBTi commitments that were approved in 2022.

(7.54.1.17) Is this target part of an overarching initiative?

Select all that apply

☑ Science Based Targets initiative

(7.54.1.18) Science Based Targets initiative official validation letter

AMGE-USA-001-OFF Certficate (003) 1.pdf

(7.54.1.19) Explain target coverage and identify any exclusions

Source 100% renewable electricity; this target covers all of Amgen's owned and operated assets; it does not include leased sales facilities.

(7.54.1.20) Target objective

Source 100% renewable electricity and continue source 100% renewable electricity through 2030

(7.54.1.21) Plan for achieving target, and progress made to the end of the reporting year

We have accelerated the purchase of clean, renewable electricity to reduce Scope 2 emissions. Progress toward the target was achieved through the installation of on-site solar photovoltaic panels and the purchase of energy attribute certificates. Amgen is also in ongoing discussions with renewable energy suppliers and brokers to identify opportunities to participate in power purchase agreements for renewable energy.
[Add row]

(7.54.2) Provide details of any other climate-related targets, including methane reduction targets.

Row 1

(7.54.2.1) Target reference number

Select from:

☑ Oth 1

(7.54.2.2) Date target was set

01/01/2019

(7.54.2.3) Target coverage

Select from:

☑ Organization-wide

(7.54.2.4) Target type: absolute or intensity

Select from:

☑ Absolute

(7.54.2.5) Target type: category & metric (target numerator if reporting an intensity target)

Low-carbon vehicles

☑ Percentage of battery electric vehicles in company fleet

(7.54.2.7) End date of base year

12/31/2019

(7.54.2.8) Figure or percentage in base year

0

(7.54.2.9) End date of target

01/01/2027

(7.54.2.10) Figure or percentage at end of date of target

30

(7.54.2.11) Figure or percentage in reporting year

12

(7.54.2.12) % of target achieved relative to base year

40.0000000000

(7.54.2.13) Target status in reporting year

Select from:

☑ Underway

(7.54.2.15) Is this target part of an emissions target?

Yes. This target is part of our overall carbon neutrality target for year-end 2027. Our target of 30% vehicle electrification will reduce Scope 1 emissions resulting from combustion of fuel in internal combustion engine vehicles.

(7.54.2.16) Is this target part of an overarching initiative?

Select all that apply

☑ Other, please specify :Amgen's 2027 Environmental Sustainability goals

(7.54.2.18) Please explain target coverage and identify any exclusions

Office vehicles used to commute to/from work

(7.54.2.19) Target objective

To accelerate decarbonization from the transportation sector

(7.54.2.20) Plan for achieving target, and progress made to the end of the reporting year

Advanced governance and leadership action to electrify fleet vehicles, including by engaging with country leads and inspiring them to take climate action by enrolling in Amgen's electric vehicles programs in the United States, the Japan-Asia Pacific (JAPAC) region and Europe, Latin America, Middle East, Africa, and Canada (ELMAC) region.
[Add row]

(7.55) Did you have emissions reduction initiatives that were active within the reporting year? Note that this can include those in the planning and/or implementation phases.

Select from:
☑ Yes

(7.55.1) Identify the total number of initiatives at each stage of development, and for those in the implementation stages, the estimated CO2e savings.

	Number of initiatives	Total estimated annual CO2e savings in metric tonnes CO2e
Under investigation	*19*	*`Numeric input*
To be implemented	*9*	*457*
Implementation commenced	*40*	*22738*
Implemented	*43*	*6242*
Not to be implemented	*0*	*`Numeric input*

[Fixed row]

(7.55.2) Provide details on the initiatives implemented in the reporting year in the table below.

Row 1

(7.55.2.1) Initiative category & Initiative type

Company policy or behavioral change

☑ Other, please specify :Carbon offsets

(7.55.2.2) Estimated annual CO2e savings (metric tonnes CO2e)

40000

(7.55.2.3) Scope(s) or Scope 3 category(ies) where emissions savings occur

Select all that apply

☑ Scope 1

(7.55.2.4) Voluntary/Mandatory

Select from:

☑ Voluntary

(7.55.2.5) Annual monetary savings (unit currency – as specified in 1.2)

0

(7.55.2.6) Investment required (unit currency – as specified in 1.2)

755000

(7.55.2.7) Payback period

Select from:

☑ No payback

(7.55.2.8) Estimated lifetime of the initiative

Select from:

☑ <1 year

(7.55.2.9) Comment

In 2024, we applied 40,000 MTCO2e of purchased high-quality carbon offsets for our Thousand Oaks, Rhode Island, and Puerto Rico sites to reduce Scope 1 direct greenhouse gas emissions from our facilities.

Row 2

(7.55.2.1) Initiative category & Initiative type

Low-carbon energy consumption

☑ Low-carbon electricity mix

(7.55.2.2) Estimated annual CO2e savings (metric tonnes CO2e)

103828

(7.55.2.3) Scope(s) or Scope 3 category(ies) where emissions savings occur

Select all that apply

☑ Scope 2 (market-based)

(7.55.2.4) Voluntary/Mandatory

Select from:

☑ Voluntary

(7.55.2.5) Annual monetary savings (unit currency – as specified in 1.2)

0

(7.55.2.6) Investment required (unit currency – as specified in 1.2)

548838

(7.55.2.7) Payback period

Select from:

☑ No payback

(7.55.2.8) Estimated lifetime of the initiative

Select from:

☑ <1 year

(7.55.2.9) Comment

In 2024, we allocated 300,061 MWh of unbundled, renewable energy certificates for our North American operations (including our Thousand Oaks, San Francisco, Rhode Island, Massachusetts, Louisville, Burnaby Puerto Rico, Deerfield, Rockville, and Ohio facilities). This is in addition to low carbon and renewable energy contracts with utility providers at our Dun Laoghaire, Waterford, Breda, Cambridge (United Kingdom), Burnaby, and San Francisco operations. The CO2e savings reported represents the incremental increase in savings additional to previous year's reductions.

Row 3

(7.55.2.1) Initiative category & Initiative type

Energy efficiency in buildings

☑ Building Energy Management Systems (BEMS)

(7.55.2.2) Estimated annual CO2e savings (metric tonnes CO2e)

835

(7.55.2.3) Scope(s) or Scope 3 category(ies) where emissions savings occur

Select all that apply

☑ Scope 1
☑ Scope 2 (location-based)
☑ Scope 2 (market-based)

(7.55.2.4) Voluntary/Mandatory

Select from:
☑ Voluntary

(7.55.2.5) Annual monetary savings (unit currency – as specified in 1.2)

534158

(7.55.2.6) Investment required (unit currency – as specified in 1.2)

264903

(7.55.2.7) Payback period

Select from:
☑ <1 year

(7.55.2.8) Estimated lifetime of the initiative

Select from:
☑ <1 year

(7.55.2.9) Comment

A Smart and Integrated Facilities program was installed at Amgen's Thousand Oaks, Rhode Island, Puerto Rico, Dun Laoghaire, Singapore, Massachusetts, and San Francisco facilities to identify energy-wasting system faults (e.g., leaking valves on air handling units) in real time, to support quick and efficient mitigation.

Row 4

(7.55.2.1) Initiative category & Initiative type

Energy efficiency in buildings

☑ Other, please specify :Move to a new energy efficient building

(7.55.2.2) Estimated annual CO2e savings (metric tonnes CO2e)

3437

(7.55.2.3) Scope(s) or Scope 3 category(ies) where emissions savings occur

Select all that apply

☑ Scope 1

☑ Scope 2 (location-based)

☑ Scope 2 (market-based)

(7.55.2.4) Voluntary/Mandatory

Select from:

☑ Voluntary

(7.55.2.5) Annual monetary savings (unit currency – as specified in 1.2)

1922676

(7.55.2.6) Investment required (unit currency – as specified in 1.2)

119031796

(7.55.2.8) Estimated lifetime of the initiative

Select from:

☑ Ongoing

(7.55.2.9) Comment

Amgen San Francisco relocated to a new building that is LEED Certified, with a modern, energy-efficient cooling tower, low-flow fixtures (faucet, kitchen sinks, urinals, toilets, etc.) and a SmartStack system, which has resulted in significant carbon savings.

Row 5

(7.55.2.1) Initiative category & Initiative type

Low-carbon energy consumption

☑ Solar PV

(7.55.2.2) Estimated annual CO2e savings (metric tonnes CO2e)

436

(7.55.2.3) Scope(s) or Scope 3 category(ies) where emissions savings occur

Select all that apply

☑ Scope 2 (location-based)

☑ Scope 2 (market-based)

(7.55.2.4) Voluntary/Mandatory

Select from:

☑ Voluntary

(7.55.2.5) Annual monetary savings (unit currency – as specified in 1.2)

158074

(7.55.2.6) Investment required (unit currency – as specified in 1.2)

166444

(7.55.2.7) Payback period

Select from:

☑ 11-15 years

(7.55.2.8) Estimated lifetime of the initiative

Select from:

☑ 11-15 years

(7.55.2.9) Comment

In addition to existing rooftop solar panels at our Breda, Netherlands facility and atop a building at our Singapore site, in 2024 we executed on the Ohio and North Carolina solar projects and installed solar panels on the roof of an additional building in Singapore.

Row 6

(7.55.2.1) Initiative category & Initiative type

Energy efficiency in buildings

☑ Heating, Ventilation and Air Conditioning (HVAC)

(7.55.2.2) Estimated annual CO2e savings (metric tonnes CO2e)

132

(7.55.2.3) Scope(s) or Scope 3 category(ies) where emissions savings occur

Select all that apply

☑ Scope 2 (location-based)

☑ Scope 2 (market-based)

(7.55.2.4) Voluntary/Mandatory

Select from:

☑ Voluntary

(7.55.2.5) Annual monetary savings (unit currency – as specified in 1.2)

63846

(7.55.2.6) Investment required (unit currency – as specified in 1.2)

0

(7.55.2.7) Payback period

Select from:

☑ No payback

(7.55.2.8) Estimated lifetime of the initiative

Select from:

☑ Ongoing

(7.55.2.9) Comment

We executed on an initiative to close laboratory fume hoods when not in use to minimize the amount of air needed to be conditioned and exhausted by the ventilation system. The scope of this project included laboratory sashes on a floor of a building at Amgen's Thousand Oaks site. This project was a simple but effective way to reduce the energy consumption of laboratory fume hoods.

Row 7

(7.55.2.1) Initiative category & Initiative type

Energy efficiency in buildings

☑ Heating, Ventilation and Air Conditioning (HVAC)

(7.55.2.2) Estimated annual CO2e savings (metric tonnes CO2e)

146

(7.55.2.3) Scope(s) or Scope 3 category(ies) where emissions savings occur

Select all that apply

☑ Scope 2 (location-based)

☑ Scope 2 (market-based)

(7.55.2.4) Voluntary/Mandatory

Select from:

☑ Voluntary

(7.55.2.5) Annual monetary savings (unit currency – as specified in 1.2)

128668

(7.55.2.6) Investment required (unit currency – as specified in 1.2)

92820

(7.55.2.8) Estimated lifetime of the initiative

Select from:

☑ Ongoing

(7.55.2.9) Comment

An energy conservation measure at the Amgen Massachusetts site monitors the concentration of chemicals in the exhaust ducts and allows the fan to set back and reduce in-flow and power consumed by eliminating minimum speed requirement until certain concentration limits are sensed (currently 2 ppm). When limits at, or above, safe concentration levels are sensed, the setback will be removed and the fan will operate to minimum required speed to maintain 3,000 FPM.

Row 8

(7.55.2.1) Initiative category & Initiative type

Transportation

☑ Company fleet vehicle efficiency

(7.55.2.2) Estimated annual CO2e savings (metric tonnes CO2e)

1903

(7.55.2.3) Scope(s) or Scope 3 category(ies) where emissions savings occur

Select all that apply

☑ Scope 1

(7.55.2.4) Voluntary/Mandatory

Select from:

☑ Voluntary

(7.55.2.5) Annual monetary savings (unit currency – as specified in 1.2)

0

(7.55.2.6) Investment required (unit currency – as specified in 1.2)

447603

(7.55.2.7) Payback period

Select from:

☑ No payback

(7.55.2.8) Estimated lifetime of the initiative

Select from:

☑ 6-10 years

(7.55.2.9) Comment

Approx. $15,000,000 was allocated for field fleet electrification from 2019 to 2027. To date, over 687 EVs have been on the road in the U.S., EU, and JAPAC regions. Level 2 home chargers were also installed in employees homes to help to assure business continuity in large territories. No payback period is expected.

Row 9

(7.55.2.1) Initiative category & Initiative type

Company policy or behavioral change

☑ Supplier engagement

(7.55.2.2) Estimated annual CO2e savings (metric tonnes CO2e)

0

(7.55.2.3) Scope(s) or Scope 3 category(ies) where emissions savings occur

Select all that apply

☑ Scope 3 category 1: Purchased goods & services

(7.55.2.4) Voluntary/Mandatory

Select from:

☑ Voluntary

(7.55.2.5) Annual monetary savings (unit currency – as specified in 1.2)

0

(7.55.2.6) Investment required (unit currency – as specified in 1.2)

83725

(7.55.2.7) Payback period

Select from:

☑ No payback

(7.55.2.8) Estimated lifetime of the initiative

Select from:

☑ 3-5 years

(7.55.2.9) Comment

As part of our 2027 environmental sustainability plan, in 2022, we established a Scope 3 supplier engagement target to engage with 73% of our suppliers by spend in key categories to support their adoption of science-based carbon emission reduction targets. This engagement covers approximately 67% of our Scope 3 emissions, from a 2019 baseline year. To help our suppliers set science-based targets, we are proud sponsors of the following industry partnerships and supplier engagement programs: (1) Energize, a program to accelerate access to renewable electricity with pharmaceutical supply chains; (2) the Responsible Health Initiative, which aims to educate suppliers about greenhouse gas emissions accounting and setting strategies; and (3) Converge, a program to reduce the environmental impacts of our fellow life science peers. Once our suppliers set science-based targets by 2027, we will request product carbon footprints to improve our accounting of carbon reductions.

Row 10

(7.55.2.1) Initiative category & Initiative type

Company policy or behavioral change

☑ Other, please specify :Employee engagement

(7.55.2.2) Estimated annual CO2e savings (metric tonnes CO2e)

0

(7.55.2.3) Scope(s) or Scope 3 category(ies) where emissions savings occur

Select all that apply

☑ Scope 1

☑ Scope 2 (location-based)
☑ Scope 2 (market-based)
☑ Scope 3 category 5: Waste generated in operations
☑ Scope 3 category 7: Employee commuting

(7.55.2.4) Voluntary/Mandatory

Select from:
☑ Voluntary

(7.55.2.5) Annual monetary savings (unit currency – as specified in 1.2)

0

(7.55.2.6) Investment required (unit currency – as specified in 1.2)

0

(7.55.2.7) Payback period

Select from:
☑ No payback

(7.55.2.8) Estimated lifetime of the initiative

Select from:
☑ Ongoing

(7.55.2.9) Comment

Amgen is committed to educating employees on sustainability topics, providing a consistent message globally regarding our sustainability, carbon, and climate ambitions. In April 2024, Amgen hosted global activities in honor of Earth Month that included employees planting trees across 11 sites. Additionally, many sites organized local Earth Month fairs and events. In September 2024, Amgen participated in the International Coastal Cleanup initiative, with participation from 17 Amgen sites. In addition to these internal efforts, Amgen offers all full-time employees a paid day dedicated to volunteering and enables employees to participate if they so choose in sustainability training, among other activities, during the workday. CO2e emissions associated with these initiatives have not been calculated.

Row 11

(7.55.2.1) Initiative category & Initiative type

Energy efficiency in production processes

☑ Other, please specify :Miscellaneous emission reduction initiatives

(7.55.2.2) Estimated annual CO2e savings (metric tonnes CO2e)

2091

(7.55.2.3) Scope(s) or Scope 3 category(ies) where emissions savings occur

Select all that apply

☑ Scope 1

☑ Scope 2 (location-based)

☑ Scope 2 (market-based)

(7.55.2.4) Voluntary/Mandatory

Select from:

☑ Voluntary

(7.55.2.6) Investment required (unit currency – as specified in 1.2)

0

(7.55.2.7) Payback period

Select from:

☑ <1 year

(7.55.2.8) Estimated lifetime of the initiative

Select from:

☑ Ongoing

(7.55.2.9) Comment

We have rolled out multiple local carbon reduction initiatives across Amgen sites, leading to decreased natural gas and electricity consumption and associated greenhouse gas emission reductions.
[Add row]

(7.55.3) What methods do you use to drive investment in emissions reduction activities?

Row 1

(7.55.3.1) Method

Select from:

☑ Other :Dedicated budget for energy efficiency; Dedicated budget for other emissions reduction activities; Internal finance mechanisms

(7.55.3.2) Comment

In 2020, we announced Amgen's commitment to invest more than $200 million to achieve our 2027 environmental plan, including our goal to achieve carbon neutrality (1) in our operations, as well as achieving our waste and water goals. This forecasted spend is independent from other company budgets and is associated with its own cost center and capital spend line item. Forecasted spend is tracked monthly. (1) Carbon neutrality goal refers to Scope 1 and 2, inclusive of our acquisition of Horizon.

Row 2

(7.55.3.1) Method

Select from:

☑ Employee engagement

(7.55.3.2) Comment

Amgen has an Environmental Sustainability Ambassador program with representatives from different non-commercial facilities and functions and support from management. The Ambassador program provides a forum for Ambassador representatives to align so that environmental sustainability is further integrated across the company, reinforcing a culture of sustainability and supporting progress toward carbon and climate-related goals. The program provides support and tools for Ambassadors to inspire, educate, and integrate best practices and embed sustainability culture within their teams; helps teams identify and collaboratively address barriers to achieving sustainability program objectives; promotes effective operations; and assures necessary resources are provided to support implementation of the sustainability program across the enterprise.

Row 3

(7.55.3.1) Method

Select from:

☑ Internal price on carbon

(7.55.3.2) Comment

Amgen uses two forms of an internal price on carbon (IPoC) to encourage the design and implementation of projects that reduce energy use and carbon emissions. The first form of an IPoC is an Investment Evaluator used in our Investment Lifecycle Management program to evaluate the purchase of innovative and efficient equipment that supports further reductions in carbon. For this evaluation, we apply an internal price of carbon of $1,600 USD per metric ton (MT) of CO2e emissions. In other words, innovative and efficiency-related sustainability projects that deliver carbon reductions of $1,600 per mt of CO2e emissions reduced (or less) are considered reasonable for inclusion in the sustainability project portfolio in support of Amgen's 2027 ambition. Based on historical projects, we determined that approximately $1600 per MT is required to drive innovative and energy efficiency scope into internal projects. The second form of an IPoC is an Internal Fee. All Amgen capital projects over $500K require a sustainability estimate of impact, including impact for carbon, waste and water. For projects that result in an increase in CO2e emissions by greater than 500 metric tons, we apply an internal fee of $1,000 USD per metric ton. Proceeds from the internal carbon fee are then added to our overall environmental sustainability budget to fund additional reduction projects. This process enables Amgen to offset our growth and associated increase in carbon footprint using the proceeds from the sustainability fee.

Row 4

(7.55.3.1) Method

Select from:

☑ Financial optimization calculations

(7.55.3.2) Comment

For each capital project requiring approval, Amgen's Investment Lifecycle Management group calculates the associated Net Present Value (NPV). Although the anticipated costs of innovative and energy-efficient projects do not always meet standard NPV expectations (e.g., for productivity initiatives), IPoC and carbon internal fees have been used to justify approval of projects that would not otherwise been prioritized based on NPV assessment because they are aligned with strategic objectives. The carbon fee is recognized numerically in the NPV calculation as a credit in year two of the NPV calculation because those funds are applied as a debit to the sustainability budget two years from the carbon project approval.

Row 5

(7.55.3.1) Method

Select from:

☑ Other :Dedicated budget for energy efficiency; Dedicated budget for low-carbon product R&D; Dedicated budget for other emissions reduction activities

(7.55.3.2) Comment

In February 2022, Amgen issued its inaugural $750 million green bond, with a 3.00% semi-annual coupon and maturing in 2029, to advance our environmental goals. Projects funded by the proceeds of the bond offering were required to meet certain sustainability criteria for eligibility. The net proceeds from the Green Bond issuance were allocated to and used in the construction of our North Carolina facility ($361 million) and the Amgen Ecovation biomanufacturing plant in Rhode Island ($74 million), the construction of our Ohio facility ($300 million), the redesign and upgrade of our wastewater treatment operations in our Singapore facility to reduce our water usage ($11 million), and to support other eco-efficient operations across our manufacturing facilities ($4 million).

Row 6

(7.55.3.1) Method

Select from:

☑ Internal incentives/recognition programs

(7.55.3.2) Comment

Our #HealthyPlanet Recognition Program recognizes Amgen employees who go above and beyond to create programs and activities that support our sustainability goals. Employees can be recognized for activities such as organizing volunteer events in the local community, implementing a sustainability policy for a department, or training employees to use equipment more efficiently in ways that measurably reduce energy, water, or waste for the Company. In 2024, we rewarded 283 employees for their contributions.

Row 7

(7.55.3.1) Method

Select from:

☑ Compliance with regulatory requirements/standards

(7.55.3.2) Comment

Amgen has developed a database of current and impending global, EU, country-wide and local carbon and climate change regulations. This database identifies associated requirements, applicability to Amgen, roles and responsibilities, and timelines to help maintain compliance. Amgen has also engaged a third-party firm to conduct biannual global sustainability regulation scanning to ensure awareness of all pending and approved reporting requirements Amgen entities are subject to. Amgen is also participating in multiple industry-specific task groups that focus on tracking and addressing climate-related regulations.
[Add row]

(7.73) Are you providing product level data for your organization's goods or services?

Select from:

☑ No, I am not providing data

(7.74) Do you classify any of your existing goods and/or services as low-carbon products?

Select from:

☑ Yes

(7.74.1) Provide details of your products and/or services that you classify as low-carbon products.

Row 1

(7.74.1.1) Level of aggregation

Select from:

☑ Group of products or services

(7.74.1.2) Taxonomy used to classify product(s) or service(s) as low-carbon

Select from:

☑ No taxonomy used to classify product(s) or service(s) as low carbon

(7.74.1.3) Type of product(s) or service(s)

Other

☑ Other, please specify :Biotechnology

(7.74.1.4) Description of product(s) or service(s)

Bio pharmaceutical drug products

(7.74.1.5) Have you estimated the avoided emissions of this low-carbon product(s) or service(s)

Select from:

☑ Yes

(7.74.1.6) Methodology used to calculate avoided emissions

Select from:

☑ Other, please specify :Internal Life Cycle Assessment methodology

(7.74.1.7) Life cycle stage(s) covered for the low-carbon product(s) or services(s)

Select from:

☑ Other, please specify :Cradle-to-drug-substance-gate

(7.74.1.8) Functional unit used

1 lot of drug substance produced

(7.74.1.9) Reference product/service or baseline scenario used

We examined the associated emissions per lot of drug substance for products that are produced at multiple sites.

(7.74.1.10) Life cycle stage(s) covered for the reference product/service or baseline scenario

Select from:

☑ Other, please specify :Cradle-to-Drug-Substance-Gate

(7.74.1.11) Estimated avoided emissions (metric tons CO2e per functional unit) compared to reference product/service or baseline scenario

3803

(7.74.1.12) Explain your calculation of avoided emissions, including any assumptions

Energy and fuel were allocated to lots of drug substance produced at all of our sites in 2024. Differences in emissions per lot for products that were produced at multiple sites were examined. Some sites were able to produce the same drug with lower emissions because of efficiency improvements or reduced energy demands (e.g., weather- or geography-related energy requirements), as well as overall productivity (sites with more production spread "overhead energy" such as HVAC across more production, leading to a lower emissions-per-lot value). Savings were then estimated for products produced at more efficient sites. Total yearly savings were estimated by multiplying the per lot savings by the lots produced at the more efficient production sites.
[Add row]

(7.79) Has your organization retired any project-based carbon credits within the reporting year?

Select from:

☑ Yes

(7.79.1) Provide details of the project-based carbon credits retired by your organization in the reporting year.

Row 1

(7.79.1.1) Project type

Select from:

☑ Other, please specify :Forest carbon

(7.79.1.2) Type of mitigation activity

Select from:

☑ Carbon removal

(7.79.1.3) Project description

Name: Boone Forestry Project ID: ACR596 Methodology: Improved Forest Management on Non-Federal U.S. Forestlands v. 1.3 Geographic Location: Kentucky, U.S. How project leads to removals/reductions: The project is located on approximately 38,272 acres of mixed hardwood forest in southeastern Kentucky. The project activity is improved forest management, with Boone Forestlands' forest management practices representing a significant improvement in the carbon storage and conservation value than higher-return, more-aggressive management regimes of industrial private lands in the region, which are characterized by shorter, even-aged rotations. Management decisions of the forest focus on sustainable, natural forest growth and maintenance harvests for essential activities, recreation, wildlife habitat, and forest health. The project ensures long-term, sustainable management of the forests, which could otherwise undergo significant commercial timber harvesting. By committing to maintain forest CO2 stocks above the regional baseline level, the project will provide significant climate benefits through carbon sequestration. (Boone Forestry Project GHG Project Plan)

(7.79.1.4) Credits retired by your organization from this project in the reporting year (metric tons CO2e)

12000

(7.79.1.5) Purpose of retirement

Select from:

☑ Voluntary offsetting

(7.79.1.6) Are you able to report the vintage of the credits at retirement?

Select from:

☑ Yes

(7.79.1.7) Vintage of credits at retirement

2019

(7.79.1.8) Were these credits issued to or purchased by your organization?

Select from:

☑ Purchased

(7.79.1.9) Carbon-crediting program by which the credits were issued

Select from:

☑ ACR (American Carbon Registry)

(7.79.1.10) Method the program uses to assess additionality for this project

Select all that apply

☑ Consideration of legal requirements

☑ Barrier analysis

(7.79.1.11) Approaches by which the selected program requires this project to address reversal risk

Select all that apply

☑ Monitoring and compensation

(7.79.1.12) Potential sources of leakage the selected program requires this project to have assessed

Select all that apply

☑ Market leakage

(7.79.1.13) Provide details of other issues the selected program requires projects to address

The project follows the requirements of the registry and methodology.

(7.79.1.14) Please explain

Serial numbers of credits and retirement date: ACR-US-596-2020-1512-28790 to 37709 (retired 12/19/2024); ACR-US-596-2019-1515-10215 to 13294 (retired 12/19/2024) Adjustments made for credits: NA

Row 2

(7.79.1.1) Project type

Select from:

☑ Other, please specify :Improved forest management

(7.79.1.2) Type of mitigation activity

Select from:

☑ Carbon removal

(7.79.1.3) Project description

Name: Darkwoods Forest Carbon Project ID: 607 Methodology: VM0012- Improved Forest Management in Temperate and Boreal Forests (LtPF), v. 1.2 Geographic Location: Creston, British Columbia, Canada How project leads to removals/reductions: The Darkwoods Forest Carbon Project achieves net GHG emission reductions and removals through the avoidance of emissions due to logging in the baseline scenario, and by increasing carbon stored by biomass growth in the retained forests on the project area in the project scenario. (VCS Project Description Document)

(7.79.1.4) Credits retired by your organization from this project in the reporting year (metric tons CO2e)

12000

(7.79.1.5) Purpose of retirement

Select from:

☑ Voluntary offsetting

(7.79.1.6) Are you able to report the vintage of the credits at retirement?

Select from:

☑ Yes

(7.79.1.7) Vintage of credits at retirement

2020

(7.79.1.8) Were these credits issued to or purchased by your organization?

Select from:

☑ Purchased

(7.79.1.9) Carbon-crediting program by which the credits were issued

Select from:

☑ VCS/Verra (Verified Carbon Standard)

(7.79.1.10) Method the program uses to assess additionality for this project

Select all that apply

☑ Investment analysis

☑ Barrier analysis

(7.79.1.11) Approaches by which the selected program requires this project to address reversal risk

Select all that apply

☑ Monitoring and compensation

(7.79.1.12) Potential sources of leakage the selected program requires this project to have assessed

Select all that apply

☑ Activity-shifting

(7.79.1.13) Provide details of other issues the selected program requires projects to address

The project follows the requirements of the registry and methodology.

(7.79.1.14) Please explain

Serial numbers of credits and retirement date: 16522-767082349-767094348-VCS-VCU-261-VER-CA-14-607-01012020-31122020-1 (retired 12/19/2024)
Adjustments made for credits: NA

Row 3

(7.79.1.1) Project type

Select from:

☑ Other, please specify :Forest carbon

(7.79.1.2) Type of mitigation activity

Select from:

☑ Carbon removal

(7.79.1.3) Project description

Name: Empire Riverlands Forestry Project ID: ACR 705 Methodology: Improved Forest Management on Non-Federal U.S. Forestlands Geographic Location: New York, USA How the project leads to GHG emissions reductions or removals: The Project is located on 47,783 acres of mostly northern hardwood forest in New York state. The project activity is improved forest management, with the Empire Riverlands Forestry Project's management practices representing a significant improvement in the carbon storage and conservation value when compared to a more typical management regime in the area for a comparably encumbered forest. Management decisions instead will focus on sustainable harvests and biomass maintenance. By committing to increasing forest carbon stocks, the project will provide significant climate benefits through carbon sequestration. (Empire Riverlands GHG Project Plan)

(7.79.1.4) Credits retired by your organization from this project in the reporting year (metric tons CO2e)

10000

(7.79.1.5) Purpose of retirement

Select from:

☑ Voluntary offsetting

(7.79.1.6) Are you able to report the vintage of the credits at retirement?

Select from:

☑ Yes

(7.79.1.7) Vintage of credits at retirement

2023

(7.79.1.8) Were these credits issued to or purchased by your organization?

Select from:

☑ Purchased

(7.79.1.9) Carbon-crediting program by which the credits were issued

Select from:

☑ ACR (American Carbon Registry)

(7.79.1.10) Method the program uses to assess additionality for this project

Select all that apply

☑ Consideration of legal requirements

☑ Barrier analysis

☑ Market penetration assessment

(7.79.1.11) Approaches by which the selected program requires this project to address reversal risk

Select all that apply

☑ Monitoring and compensation

(7.79.1.12) Potential sources of leakage the selected program requires this project to have assessed

Select all that apply

☑ Market leakage

(7.79.1.13) Provide details of other issues the selected program requires projects to address

The project follows the requirements of the registry and methodology.

(7.79.1.14) Please explain

Serial numbers of credits and retirement date: ACR-US-705-2022-2173-1 to 939; (retired 12/19/2024); ACR-US-705-2021-2176-2001 to 11061 (retired 12/19/2024)
Adjustments made for credits: NA

Row 4

(7.79.1.1) Project type

Select from:

☑ HFCs

(7.79.1.2) Type of mitigation activity

Select from:

☑ Emissions reduction

(7.79.1.3) Project description

Name: Foam Blowing Agent Project 001P ID: ACR833 Methodology: Transition to Advanced Formulation Blowing Agents in Foam Manufacturing and Use v. 3.0 Geographic Location: Missouri, Texas How the project leads to GHG emissions reductions or removals: The Project transitions foam manufacturing from high global warming potential blowing agents to blowing agents with lower global warming potential at multiple facilities in the United States, reducing emissions. (Foam Blowing Agent Project 001P GHG Project Plan)

(7.79.1.4) Credits retired by your organization from this project in the reporting year (metric tons CO2e)

12000

(7.79.1.5) Purpose of retirement

Select from:

☑ Voluntary offsetting

(7.79.1.6) Are you able to report the vintage of the credits at retirement?

Select from:

☑ Yes

(7.79.1.7) Vintage of credits at retirement

2022

(7.79.1.8) Were these credits issued to or purchased by your organization?

Select from:

☑ Purchased

(7.79.1.9) Carbon-crediting program by which the credits were issued

Select from:

☑ ACR (American Carbon Registry)

(7.79.1.10) Method the program uses to assess additionality for this project

Select all that apply

☑ Consideration of legal requirements

☑ Standardized Approaches

(7.79.1.11) Approaches by which the selected program requires this project to address reversal risk

Select all that apply

☑ No risk of reversal

(7.79.1.12) Potential sources of leakage the selected program requires this project to have assessed

Select all that apply

☑ Not assessed

(7.79.1.13) Provide details of other issues the selected program requires projects to address

Project proponents must only show their project falls into one of the Eligible Foam Applications of the Methodology. The Project is in the Rigid PU injected foam application within six sub-applications (Marine flotation or buoyancy, HVAC, Refrigerated transport, Small retail food refrigeration, Garage and entry doors, Industrial refrigeration systems. This is an eligible foam application under the Methodology.

(7.79.1.14) Please explain

Serial numbers of credits and retirement date: ACR-US-833-2022-2-33-250001 to 2620000 (retired 12/19/2024) Adjustments made for credits: NA

[Add row]

C9. Environmental performance - Water security

(9.1) Are there any exclusions from your disclosure of water-related data?

Select from:

☑ Yes

(9.1.1) Provide details on these exclusions.

Row 1

(9.1.1.1) Exclusion

Select from:

☑ Facilities

(9.1.1.2) Description of exclusion

The scope of our data collection in 2024 includes 15 sites composed of manufacturing, R&D, and distribution facilities in the United States (including Puerto Rico), Netherlands, United Kingdom, Ireland, Canada, and Singapore. These facilities account for approximately 87% of our operations based on square footage. The remaining 13% is primarily shared office and administrative spaces. Amgen is not a significant consumer of water in administrative spaces when compared to our manufacturing, R&D, and distribution facilities.

(9.1.1.3) Reason for exclusion

Select from:

☑ Other, please specify :The remaining 13% is primarily shared office and administrative spaces. Amgen is not a significant consumer of water in administrative spaces when compared to our manufacturing, R&D, and distribution facilities.

(9.1.1.7) Percentage of water volume the exclusion represents

Select from:

☑ 1-5%

(9.1.1.8) Please explain

The scope of our data collection in 2024 includes 15 sites composed of manufacturing, R&D, and distribution facilities in the United States (including Puerto Rico), Netherlands, United Kingdom, Ireland, Canada, and Singapore. These facilities account for approximately 87% of our operations based on square footage. The remaining 13% is primarily shared office and administrative spaces. Amgen is not a significant consumer of water in administrative spaces when compared to our manufacturing, R&D, and distribution facilities.
[Add row]

(9.2) Across all your operations, what proportion of the following water aspects are regularly measured and monitored?

Water withdrawals – total volumes

(9.2.1) % of sites/facilities/operations

Select from:
☑ 76-99

(9.2.2) Frequency of measurement

Select from:
☑ Monthly

(9.2.3) Method of measurement

Our total water withdrawals are regularly measured and monitored at our global manufacturing, R&D, and distribution facilities. Total water withdrawals are monitored by site water meters that enable real-time monitoring that is integrated into our building management and collected in our centralized data tracking system. Amgen tracks historical water consumption across our network, including a geographic footprint map for each site's water usage.

(9.2.4) Please explain

As a raw material, sourcing quality water is important for Amgen's business of discovering, developing, and manufacturing life-saving medicines. Potential supply restrictions from municipal water supplies could affect our manufacturing processes. We strive to use water efficiently by assessing and implementing water conservation and reuse strategies. Amgen's dedicated sustainability team manages water consumption data in our environmental sustainability management software Our tracking of total water withdrawals allows us to incorporate sites' consumption and efficiency into management review dashboards and visualize building specific water consumption by site across our largest facilities, and annually our environmental data is verified by an independent third party and water withdrawal

total volumes are included in our Sustainability Highlights Report. Our 'total water withdrawals' KPI enables us to monitor consumption and benchmark water use efficiency consistently.

Water withdrawals – volumes by source

(9.2.1) % of sites/facilities/operations

Select from:

☑ 76-99

(9.2.2) Frequency of measurement

Select from:

☑ Monthly

(9.2.3) Method of measurement

Our water withdrawals by source are regularly monitored and measured at our global manufacturing, R&D, and distribution facilities using utility water and internal groundwater withdrawal meters. This real-time monitoring is integrated with our building management system and collected in our centralized data tracking system. Annually, each of our sites performs a water balance that tracks the source and volume of our water withdrawals, and Amgen tracks historical site-specific water consumption.

(9.2.4) Please explain

As a raw material, sourcing quality water is vital for Amgen's business of discovering, developing, and manufacturing life-saving medicines. Potential supply restrictions from municipal water supplies could affect our manufacturing processes. We strive to use water efficiently in our operations by assessing and implementing water conservation and reuse strategies including water-reduction projects. Our tracking of total water withdrawals in our operations allows us to incorporate sites' consumption and efficiency into management review dashboards and visualize building specific water consumption by site across our largest facilities. Amgen has a dedicated global sustainability team that regularly manages site-specific water consumption data by source in our environmental sustainability management software. Annually, we verify our environmental data by an independent third party and report water withdrawal total volumes in our Sustainability Highlights Report.

Water withdrawals quality

(9.2.1) % of sites/facilities/operations

Select from:

☑ 26-50

(9.2.2) Frequency of measurement

Select from:

☑ Monthly

(9.2.3) Method of measurement

High- and ultra-high-purity water is essential for our manufacturing processes to produce our medicines. We continuously monitor the quality of our purchased water supplies at our manufacturing facilities and at other operations where water quality is important. As required, water monitoring is performed in compliance with regulations related to drinking water standards and pharmaceutical manufacturing.

(9.2.4) Please explain

As a raw material, sourcing quality water is vital for Amgen's business of discovering, developing, and manufacturing life-saving medicines. Potential supply restrictions from municipal water supplies could affect our manufacturing processes. To mitigate our water footprint, we strive to use water efficiently in our operations by assessing, identifying, and implementing water conservation and reuse strategies that include water-reduction projects across our operations.

Water discharges – total volumes

(9.2.1) % of sites/facilities/operations

Select from:

☑ 76-99

(9.2.2) Frequency of measurement

Select from:

☑ Daily

(9.2.3) Method of measurement

Our total water discharge volumes are regularly measured and monitored at our global manufacturing, R&D, and distribution facilities. Total water discharges are monitored by site water meters enabling real-time monitoring that is integrated into our building management and collected in our centralized system. Annually, each of our sites performs a water balance that tracks the total volume of water discharged.

(9.2.4) Please explain

Amgen has a global sustainability team that regularly collects, analyzes, verifies, and centralizes site-specific water discharges by volume in our environmental sustainability management software on an annual basis. Our tracking of total volumes of water discharges in our operations allows us to incorporate sites' consumption, efficiency, and water balances into management review dashboards and annually we verify our environmental data by an independent third party.

Water discharges – volumes by destination

(9.2.1) % of sites/facilities/operations

Select from:

☑ 76-99

(9.2.2) Frequency of measurement

Select from:

☑ Daily

(9.2.3) Method of measurement

Our total water discharges by destination are regularly measured and monitored at our global manufacturing, R&D, and distribution facilities. Total water discharges by destination are monitored by site water meters that enable real-time monitoring that is integrated into our building management and collected in our centralized system. Annually, each of our sites performs a water balance that tracks the total volume of water discharged by destination.

(9.2.4) Please explain

Amgen has a global sustainability team that regularly collects, analyzes, verifies, and centralizes site-specific water discharges volumes per destination in our environmental sustainability management software on an annual basis. Our tracking of water discharges - volumes by destination in our operations allows us to incorporate sites' consumption, efficiency, and water balances into management review dashboards and annually we verify our environmental data by an independent third party.

Water discharges – volumes by treatment method

(9.2.1) % of sites/facilities/operations

Select from:

☑ 76-99

(9.2.2) Frequency of measurement

Select from:

☑ Daily

(9.2.3) Method of measurement

Our total water discharges by treatment method are regularly measured and monitored at our global manufacturing, R&D, and distribution facilities. Annually, each of our sites performs a water balance that assesses and confirms treatment methods in order to track the total volume of water discharged by treatment method at our sites.

(9.2.4) Please explain

Our total water discharges by treatment method are regularly measured and monitored at our global manufacturing, R&D, and distribution facilities. Annually, each of our sites performs a water balance that assesses and confirms treatment methods in order to track the total volume of water discharged by treatment method at our sites.

Water discharge quality – by standard effluent parameters

(9.2.1) % of sites/facilities/operations

Select from:

☑ 76-99

(9.2.2) Frequency of measurement

Select from:

☑ Quarterly

(9.2.3) Method of measurement

Our water discharge quality by standard effluent parameters is regularly measured and monitored at our global manufacturing, R&D, and distribution facilities. We monitor and report standard effluent parameters where required by regulations.

(9.2.4) Please explain

Our water discharge quality by standard effluent parameters is regularly measured and monitored at our global manufacturing, R&D, and distribution facilities. We monitor and report standard effluent parameters where required by regulations.

Water discharge quality – emissions to water (nitrates, phosphates, pesticides, and/or other priority substances)

(9.2.1) % of sites/facilities/operations

Select from:

☑ 1-25

(9.2.2) Frequency of measurement

Select from:

☑ Quarterly

(9.2.3) Method of measurement

Our water discharge quality for emissions such as nitrates, phosphates, and other priority substances is measured and monitored in milligrams per liter at some of our manufacturing facilities on a quarterly basis as required by local wastewater regulatory agencies.

(9.2.4) Please explain

Our tracking of water discharge quality for emissions of some priority substances allows us to comply with local discharge permit and surcharge limitations. We mitigate these priority substances at some of our manufacturing sites by performing wastewater assessments, pre-treatment and/or segregation for off-site disposal.

Water discharge quality – temperature

(9.2.1) % of sites/facilities/operations

Select from:

☑ 26-50

(9.2.2) Frequency of measurement

Select from:

☑ Daily

(9.2.3) Method of measurement

Our water discharge temperatures are regularly measured and monitored at our global manufacturing, R&D, and distribution facilities. We monitor and report water discharge temperature where it is required by regulations.

(9.2.4) Please explain

Our water discharge temperatures are regularly measured and monitored at our global manufacturing, R&D, and distribution facilities. We monitor and report water discharge temperature where it is required by regulations.

Water consumption – total volume

(9.2.1) % of sites/facilities/operations

Select from:

☑ 76-99

(9.2.2) Frequency of measurement

Select from:

☑ Monthly

(9.2.3) Method of measurement

Our total water consumption is regularly measured and monitored at our global manufacturing, R&D, and distribution facilities. Total water consumption is collected in our centralized data tracking system. Annually, each of our sites performs a water balance that tracks the total water consumption at our sites which enables us to benchmark progress and track our sites' water efficiency.

(9.2.4) Please explain

Amgen has a global sustainability team that regularly collects, analyzes, verifies, and centralizes site-specific water consumption data in our environmental sustainability management software on an annual basis. Our tracking of total water consumption volumes in our operations allows us to incorporate sites' consumption and efficiency, and water balances into management review dashboards and annually we verify our environmental data by an independent third party.

Water recycled/reused

(9.2.1) % of sites/facilities/operations

Select from:

☑ 76-99

(9.2.2) Frequency of measurement

Select from:

☑ Daily

(9.2.3) Method of measurement

Our water recycled/reused is regularly measured and monitored at our global manufacturing, R&D, and distribution facilities. Annually, each of our sites performs a water balance that tracks the total volume of water recycled/reused at our sites based on equipment and engineering calculations, like the recycle of reverse osmosis unit reject water and wastewater treatment plant reuse streams. Total water recycled/reused is collected in our centralized system to benchmark our water efficiency.

(9.2.4) Please explain

The availability of sufficient amounts of recycled water is important in our operations. Using recycled water reduces our demand for water from local municipalities and aquifers. We identify and implement water conservation and reuse into our water-intensive systems where feasible. We use recycled and produced water in non-manufacturing operations like cooling towers and boilers; we reuse reverse osmosis reject water, we return and reuse steam condensate, and we optimize cycles of concentration on cooling towers, among other projects. Amgen has a global sustainability team that regularly collects, analyzes, verifies, and centralizes site-specific water recycling data in our environmental sustainability management software on an annual basis. Our tracking of water recycled/reused in our operations allows us to incorporate sites' consumption and efficiency, and water balances into management review dashboards and annually we verify our environmental data by an independent third party.

The provision of fully-functioning, safely managed WASH services to all workers

(9.2.1) % of sites/facilities/operations

Select from:

☑ 100%

(9.2.2) Frequency of measurement

Select from:

☑ Continuously

(9.2.3) Method of measurement

Amgen staff are provided with water that is sourced from local drinking water purveyors and that is safe for drinking, sanitation, and hygiene.

(9.2.4) Please explain

Amgen staff are provided with water that is sourced from local drinking water purveyors and that is safe for drinking, sanitation, and hygiene.
[Fixed row]

(9.2.2) What are the total volumes of water withdrawn, discharged, and consumed across all your operations, how do they compare to the previous reporting year, and how are they forecasted to change?

Total withdrawals

(9.2.2.1) Volume (megaliters/year)

2188

(9.2.2.2) Comparison with previous reporting year

Select from:

☑ Higher

(9.2.2.3) Primary reason for comparison with previous reporting year

Select from:

☑ Increase/decrease in business activity

(9.2.2.4) Five-year forecast

Select from:

☑ Higher

(9.2.2.5) Primary reason for forecast

Select from:

☑ Increase/decrease in business activity

(9.2.2.6) Please explain

Total withdrawals were higher in 2024 than in 2023 due to increased business activity, including increased manufacturing output to serve more patients globally, our acquisition of Horizon Therapeutics plc, and our new manufacturing facility in Ohio. Water is an important resource for our operations to produce our medicines for our patients worldwide. We recognize that water is vital in every community in which we operate, so we strive to utilize water responsibly. We expect our increased business activity to increase our water consumption. While water withdrawals are expected to increase, we continue to make steady progress toward Amgen's 2027 target to reduce water consumption by 40% from our 2019 baseline. In 2024, we achieved 488,000 cubic meters (CM) of cumulative water reductions across the Amgen enterprise towards our goal to reduce 858,500 CM by 2027.

Total discharges

(9.2.2.1) Volume (megaliters/year)

1654

(9.2.2.2) Comparison with previous reporting year

Select from:

☑ Higher

(9.2.2.3) Primary reason for comparison with previous reporting year

Select from:

☑ Increase/decrease in business activity

(9.2.2.4) Five-year forecast

Select from:

☑ Higher

(9.2.2.5) Primary reason for forecast

Select from:

☑ Increase/decrease in business activity

(9.2.2.6) Please explain

Total discharges were higher in 2024 than in 2023 due to increased business activity that includes increased manufacturing output to serve more patients globally, our acquisition of Horizon Therapeutics plc and our new manufacturing facility in Ohio. Water is an important resource for our operations to produce our medicines for our patients worldwide. We recognize that water is vital in every community in which we operate, so we strive to utilize water responsibly. We expect our increased business activity to increase our water discharges. While water discharges are expected to increase, we continue to make steady progress toward Amgen's 2027 target to reduce water consumption by 40% from our 2019 baseline (considering only verified reduction projects and not changes associated with the contraction or expansion of the Company). In 2024, we achieved 488,000 CM of cumulative water reductions across the Amgen enterprise towards our goal to reduce 858,500 CM by 2027.

Total consumption

(9.2.2.1) Volume (megaliters/year)

545

(9.2.2.2) Comparison with previous reporting year

Select from:

☑ Higher

(9.2.2.3) Primary reason for comparison with previous reporting year

Select from:

☑ Increase/decrease in business activity

(9.2.2.4) Five-year forecast

Select from:

☑ Higher

(9.2.2.5) Primary reason for forecast

Select from:

☑ Increase/decrease in business activity

(9.2.2.6) Please explain

Total consumption was higher in 2024 than in 2023 due to increased business activity that includes increased manufacturing output to serve more patients globally, our acquisition of Horizon Therapeutics plc and our new manufacturing facility in Ohio. Water is an important resource for our operations to produce our medicines for our patients worldwide. We recognize that water is vital in every community in which we operate, so we strive to utilize water responsibly. We expect our increased business activity to increase our water consumption in the future. While water consumption is expected to increase, we continue to make steady progress toward Amgen's 2027 target to reduce water consumption by 858,500 CM. In 2024, we achieved 488,000 cumulative water reductions across the Amgen enterprise. [Fixed row]

(9.2.4) Indicate whether water is withdrawn from areas with water stress, provide the volume, how it compares with the previous reporting year, and how it is forecasted to change.

(9.2.4.1) Withdrawals are from areas with water stress

Select from:

☑ Yes

(9.2.4.2) Volume withdrawn from areas with water stress (megaliters)

2040

(9.2.4.3) Comparison with previous reporting year

Select from:

☑ Higher

(9.2.4.4) Primary reason for comparison with previous reporting year

Select from:

☑ Increase/decrease in business activity

(9.2.4.5) Five-year forecast

Select from:

☑ Higher

(9.2.4.6) Primary reason for forecast

Select from:

☑ Increase/decrease in business activity

(9.2.4.7) % of total withdrawals that are withdrawn from areas with water stress

93.24

(9.2.4.8) Identification tool

Select all that apply

☑ WRI Aqueduct

☑ WWF Water Risk Filter

(9.2.4.9) Please explain

Amgen recognizes that water is vital in every community in which we operate, so we strive to utilize water responsibly. Therefore, Amgen takes a holistic approach to our annual water-related risk assessment to improve our water stewardship in the communities in which we operate and to support our long-term direct business operations to serve our patients. In 2024, Amgen identified several sites in our operations located in water-stressed areas using the WWF Water Risk Filter and WRI

Aqueduct's Water Risk Atlas. Using the WWF Water Risk Filter's Basin & Organizational Risk Results, we identified Amgen sites with water stress using the Physical Basin Risk Score of 2.6 or higher (Medium Risk or Higher) which considers water availability, drought, flooding, water quality, and ecosystem services. Using the WRI Aqueduct Water Risk Atlas tool, we identified Amgen sites with water stress using a Water Stress Score of "Medium-High (20-40%) or higher. Our percentage of water withdrawals from water-stressed regions in 2024 was higher than in 2023 due to increased business activities as our volume driven growth aims to serve more patients globally, including our acquisition of Horizon Therapeutics plc and our new facility in Ohio. The WWF Water Risk Filter and the WRI Aqueduct Water Risk Atlas enable us to assess a range of water risks into our water-reduction strategy and helps us prioritize water-reduction projects at Amgen locations where water stress is most prevalent. Amgen Ecovation™ integrates innovation and sustainability into the upfront design and execution of our new laboratory, manufacturing, and administrative buildings, resulting in highly resource efficient biomanufacturing that reduces water consumption. In 2024, we continued our internal Sustainability Maturity Matrix created the year prior which outlines best practices for Amgen- sites to reduce water use. This tool also allows global implementation, measurement and tracking of these practices by site, as appropriate, and supports the sharing of lessons and ideas across sites. Amgen has also created an internal enterprise analytics tool to empower our facilities to visualize the different water-efficiency projects being executed across the network and historical water efficiency projects. This tool further enables the visualization of site-specific water consumption on a geographic map and building-specific water consumption for our largest facilities. In 2024, we achieved 488,000 CM of cumulative water reductions across the Amgen enterprise as we make steady progress towards our goal to reduce 858,500 CM by 2027. Water reductions across our Amgen network are primarily achieved through the implementation of water-efficiency projects, design of innovative new facilities, water treatment & recycling efforts, and other strategic initiatives such as the prioritization of our water-stressed sites. For instance, in 2024 we saved 91,000 CM of water via optimized control of an ultra-high-purity water production system at our Puerto Rico manufacturing facility.
[Fixed row]

(9.2.7) Provide total water withdrawal data by source.

Fresh surface water, including rainwater, water from wetlands, rivers, and lakes

(9.2.7.1) Relevance

Select from:
☑ Relevant

(9.2.7.2) Volume (megaliters/year)

0.1

(9.2.7.3) Comparison with previous reporting year

Select from:
☑ Higher

(9.2.7.4) Primary reason for comparison with previous reporting year

Select from:

☑ Increase/decrease in business activity

(9.2.7.5) Please explain

Rainwater is utilized at our new Waterford, Ireland site, which was part of the Horizon Therapeutics plc acquisition. Amgen's rainwater consumption makes up < 1% of Amgen's total water withdrawn.

Brackish surface water/Seawater

(9.2.7.1) Relevance

Select from:

☑ Not relevant

(9.2.7.5) Please explain

Brackish surface water / seawater is not relevant because we do not currently withdraw from brackish surface water/seawater in our operations.

Groundwater – renewable

(9.2.7.1) Relevance

Select from:

☑ Relevant

(9.2.7.2) Volume (megaliters/year)

19

(9.2.7.3) Comparison with previous reporting year

Select from:

☑ Higher

(9.2.7.4) Primary reason for comparison with previous reporting year

Select from:

☑ Increase/decrease in business activity

(9.2.7.5) Please explain

Groundwater-Renewable, is utilized at two of our major manufacturing sites, which makes up < 1% of Amgen's total water withdrawn. Our withdrawal of renewable groundwater in 2024 was higher than in 2023 due to increased business activity to serve more patients, including increased manufacturing output, our acquisition of Horizon Therapeutics plc, and our new manufacturing facility in Ohio. For instance, we replaced existing water urinals with waterless urinals at one of the two manufacturing sites that utilize renewable groundwater.

Groundwater – non-renewable

(9.2.7.1) Relevance

Select from:

☑ Not relevant

(9.2.7.5) Please explain

Nonrenewable groundwater is not relevant because we do not currently withdraw from non-renewable ground water in our operations.

Produced/Entrained water

(9.2.7.1) Relevance

Select from:

☑ Not relevant

(9.2.7.5) Please explain

Produced / Entrained water is not relevant because we do not currently use Produced/Entrained water in our operations.

Third party sources

(9.2.7.1) Relevance

Select from:
☑ Relevant

(9.2.7.2) Volume (megaliters/year)

2169

(9.2.7.3) Comparison with previous reporting year

Select from:
☑ Higher

(9.2.7.4) Primary reason for comparison with previous reporting year

Select from:
☑ Increase/decrease in business activity

(9.2.7.5) Please explain

Water from third party municipal sources is an important element of producing our potentially life saving medicines. Our withdrawal of municipal water in 2024 was higher than in 2023 due to increased business activity, including increased manufacturing output to serve more patients globally, our acquisition of Horizon Therapeutics plc, and our new manufacturing facility in Ohio.
[Fixed row]

(9.2.8) Provide total water discharge data by destination.

Fresh surface water

(9.2.8.1) Relevance

Select from:

☑ Relevant but volume unknown

(9.2.8.5) Please explain

Amgen discharges stormwater and irrigation run-off to surface water. Our manufacturing sites provide engineered stormwater treatment controls prior to discharge to municipal stormwater drains.

Brackish surface water/seawater

(9.2.8.1) Relevance

Select from:

☑ Not relevant

(9.2.8.5) Please explain

Amgen does not discharge water to surface water. Amgen discharges primarily to third party municipal systems and secondarily to groundwater.

Groundwater

(9.2.8.1) Relevance

Select from:

☑ Relevant

(9.2.8.2) Volume (megaliters/year)

196

(9.2.8.3) Comparison with previous reporting year

Select from:

☑ Higher

(9.2.8.4) Primary reason for comparison with previous reporting year

Select from:

☑ Increase/decrease in business activity

(9.2.8.5) Please explain

Landscape irrigation is discharged directly to the environment. Discharge to groundwater was higher in 2024 than 2023 due to increased business activity. In Ohio, post-construction native plants are being irrigated, but irrigation will not become part of routine operation. Our water discharge volumes are regularly measured and monitored at our global manufacturing, R&D, and distribution facilities in real time by site water meters and integrated into our building management system. We invest in water-smart innovations like improving irrigation efficiency and using native and drought-tolerant landscapes. We continue to make steady progress toward our 2027 target to reduce water by 40% from a 2019 baseline (including only verified reduction projects, not changes associated with the contraction or expansion of the Company (e.g., excluding Horizon). In 2024, we achieved 488,000 CM of cumulative water reductions across the Amgen enterprise towards our goal to reduce 858,500 CM by 2027.

Third-party destinations

(9.2.8.1) Relevance

Select from:

☑ Relevant

(9.2.8.2) Volume (megaliters/year)

1458

(9.2.8.3) Comparison with previous reporting year

Select from:

☑ Higher

(9.2.8.4) Primary reason for comparison with previous reporting year

Select from:

☑ Increase/decrease in business activity

(9.2.8.5) Please explain

Most of our discharged water is treated at municipal Publicly Owned Treatment Works. Our total water discharge volumes are regularly measured and monitored at our global manufacturing, R&D, and distribution facilities by site water meters that enable real-time monitoring that is integrated into our building management system. In 2024 we continued implementing water-saving and water-efficiency projects across our network. Our discharged water was higher in 2024 than in 2023 due to increased business activity, including higher manufacturing output as we serve more patients globally, our investments in our new Ohio facility, and our Horizon acquisition. While we expect our increased business activity to increase our water consumption, we continue to make steady progress toward Amgen's 2027 target to reduce water consumption by 40% from our 2019 baseline. In 2024, we achieved 488,000 CM of cumulative water reductions across the Amgen enterprise towards our goal to reduce 858,500 CM by 2027
[Fixed row]

(9.2.9) Within your direct operations, indicate the highest level(s) to which you treat your discharge.

Tertiary treatment

(9.2.9.1) Relevance of treatment level to discharge

Select from:
☑ Relevant

(9.2.9.2) Volume (megaliters/year)

336

(9.2.9.3) Comparison of treated volume with previous reporting year

Select from:
☑ Lower

(9.2.9.4) Primary reason for comparison with previous reporting year

Select from:
☑ Investment in water-smart technology/process

(9.2.9.5) % of your sites/facilities/operations this volume applies to

Select from:

☑ 1-10

(9.2.9.6) Please explain

Tertiary treatment is conducted at our manufacturing facility in Puerto Rico and at our Singapore manufacturing facility. Both Puerto Rico and Singapore sites have their own wastewater treatment plant on-site that enables us to recapture and reuse water from different sources such as utility drains, process drains, and personnel use drains. Tertiary treatment was lower in 2024 than in 2023 as both sites aim to reduce their water consumption via water reduction and reuse projects. Both sites have biological and reverse osmosis wastewater treatment capabilities that are directly measured. All of our facilities are expected to maintain the necessary compliance as required by their local regulatory authorities in their respective geographical location. The volume of tertiary treatment discharged is expected to increase.

Secondary treatment

(9.2.9.1) Relevance of treatment level to discharge

Select from:

☑ Relevant

(9.2.9.2) Volume (megaliters/year)

337

(9.2.9.3) Comparison of treated volume with previous reporting year

Select from:

☑ Higher

(9.2.9.4) Primary reason for comparison with previous reporting year

Select from:

☑ Increase/decrease in business activity

(9.2.9.5) % of your sites/facilities/operations this volume applies to

Select from:

☑ 1-10

(9.2.9.6) Please explain

Secondary treatment is conducted at our manufacturing facility in Rhode Island, which provides secondary treatment to wastewater discharges. Secondary treatment wastewater volumes were higher in 2024 than in 2023 due to our increased manufacturing output to serve more patients globally. All our facilities are expected to maintain the necessary compliance as required by their local regulatory authorities in their respective geographical location. We anticipate that our secondary treatment wastewater volumes may increase due to our volume driven growth to reach more patients.

Primary treatment only

(9.2.9.1) Relevance of treatment level to discharge

Select from:

☑ Relevant

(9.2.9.2) Volume (megaliters/year)

757

(9.2.9.3) Comparison of treated volume with previous reporting year

Select from:

☑ Higher

(9.2.9.4) Primary reason for comparison with previous reporting year

Select from:

☑ Increase/decrease in business activity

(9.2.9.5) % of your sites/facilities/operations this volume applies to

Select from:

☑ 61-70

(9.2.9.6) Please explain

Primary treatment is conducted in our direct operations as many of our sites have equalization tanks with neutralization capabilities. These systems discharge to municipal wastewater treatment plants. Primary treatment volumes were higher in 2024 than in 2023 because of increased business activity, including higher manufacturing output as we serve more patients globally, our investments in our new Ohio facility, and our Horizon Therapeutics plc acquisition. All our facilities are expected to maintain the necessary compliance as required by their local regulatory authorities in their respective geographical location. We anticipate that our primary treatment may increase due to the growth of our business.

Discharge to the natural environment without treatment

(9.2.9.1) Relevance of treatment level to discharge

Select from:

☑ Relevant

(9.2.9.2) Volume (megaliters/year)

196

(9.2.9.3) Comparison of treated volume with previous reporting year

Select from:

☑ Higher

(9.2.9.4) Primary reason for comparison with previous reporting year

Select from:

☑ Increase/decrease in business activity

(9.2.9.5) % of your sites/facilities/operations this volume applies to

Select from:

☑ 31-40

(9.2.9.6) Please explain

Discharge to the natural environment without treatment is relevant because landscape irrigation at our sites is released directly to the environment. Water released into the natural environment without treatment was higher in 2024 than in 2023 because of increased business activity, including higher manufacturing output as we serve more patients globally, our investments in our new Ohio facility, and our Horizon Therapeutics plc acquisition. As aligned with our 2027 Environmental Sustainability Plan to reduce water by 40% from a 2019 baseline, we are investing in water-smart technologies/ processes in our operations such as the implementation of more efficient irrigation systems and incorporating native and drought tolerant landscape vegetation at our sites. For instance, our Thousand Oaks, California, campus, one of our most water-stressed sites, contains drought-tolerant plants to reduce our water consumption. All our facilities are expected to maintain the necessary compliance as required by their local regulatory authorities in their respective geographical location. We anticipate that our discharge to the natural environment without treatment may increase due to our volume driven growth to reach more patients.

Discharge to a third party without treatment

(9.2.9.1) Relevance of treatment level to discharge

Select from:

☑ Relevant

(9.2.9.2) Volume (megaliters/year)

28

(9.2.9.3) Comparison of treated volume with previous reporting year

Select from:

☑ Higher

(9.2.9.4) Primary reason for comparison with previous reporting year

Select from:

☑ Increase/decrease in business activity

(9.2.9.5) % of your sites/facilities/operations this volume applies to

Select from:

☑ 11-20

(9.2.9.6) Please explain

In 2024, discharge to a third party without treatment was higher than 2023 because of increased manufacturing output as we serve more patients globally, our investments in our new Ohio facility, and our Horizon Therapeutics plc acquisition. Discharge to a third party without treatment is relevant because some of our administrative and distribution facilities do not require pre-treatment prior to discharge to municipal wastewater treatment plants. For example, our site in Cambridge, United Kingdom is primarily an administrative Amgen site, so their water discharge goes without treatment to a third party for treatment. All our facilities are expected to maintain the necessary compliance as required by their local regulatory authorities in their respective geographical location. We anticipate that our discharge to a third party without treatment may increase.

Other

(9.2.9.1) Relevance of treatment level to discharge

Select from:

☑ Not relevant

(9.2.9.6) Please explain

No other discharges identified in scope.
[Fixed row]

(9.2.10) Provide details of your organization's emissions of nitrates, phosphates, pesticides, and other priority substances to water in the reporting year.

(9.2.10.4) Please explain

Amgen does not currently quantify emissions of nitrates, phosphates, pesticides, or other priority substances. We comply with local wastewater effluent limits, where applicable.
[Fixed row]

(9.3) In your direct operations and upstream value chain, what is the number of facilities where you have identified substantive water-related dependencies, impacts, risks, and opportunities?

Direct operations

(9.3.1) Identification of facilities in the value chain stage

Select from:

☑ Yes, we have assessed this value chain stage and identified facilities with water-related dependencies, impacts, risks, and opportunities

(9.3.2) Total number of facilities identified

2

(9.3.3) % of facilities in direct operations that this represents

Select from:

☑ 1-25

(9.3.4) Please explain

Two of Amgen's 15 facility locations have substantive water-related dependencies, impacts, risks,and opportunities (Amgen Thousand Oaks located in Thousand Oaks, CA and AML in Juncos, Puerto Rico).

Upstream value chain

(9.3.1) Identification of facilities in the value chain stage

Select from:

☑ No, we have not assessed this value chain stage for facilities with water-related dependencies, impacts, risks, and opportunities, but we are planning to do so in the next 2 years

(9.3.4) Please explain

Amgen plans to expand its water risk assessment to include key upstream value chain.
[Fixed row]

(9.3.1) For each facility referenced in 9.3, provide coordinates, water accounting data, and a comparison with the previous reporting year.

Row 1

(9.3.1.1) Facility reference number

Select from:

☑ Facility 1

(9.3.1.2) Facility name (optional)

Amgen Manufacturing Limited

(9.3.1.3) Value chain stage

Select from:

☑ Direct operations

(9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☑ Risks

(9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☑ Yes, withdrawals and discharges

(9.3.1.7) Country/Area & River basin

Puerto Rico

☑ Other, please specify :Rio Grande de Loíza

(9.3.1.8) Latitude

18.2274

(9.3.1.9) Longitude

-65.92589

(9.3.1.10) Located in area with water stress

Select from:

☑ Yes

(9.3.1.13) Total water withdrawals at this facility (megaliters)

641

(9.3.1.14) Comparison of total withdrawals with previous reporting year

Select from:

☑ Lower

(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes

0

(9.3.1.16) Withdrawals from brackish surface water/seawater

0

(9.3.1.17) Withdrawals from groundwater - renewable

2

(9.3.1.18) Withdrawals from groundwater - non-renewable

0

(9.3.1.19) Withdrawals from produced/entrained water

0

(9.3.1.20) Withdrawals from third party sources

639

(9.3.1.21) Total water discharges at this facility (megaliters)

361

(9.3.1.22) Comparison of total discharges with previous reporting year

Select from:

☑ Lower

(9.3.1.23) Discharges to fresh surface water

0

(9.3.1.24) Discharges to brackish surface water/seawater

0

(9.3.1.25) Discharges to groundwater

53

(9.3.1.26) Discharges to third party destinations

308

(9.3.1.27) Total water consumption at this facility (megaliters)

294

(9.3.1.28) Comparison of total consumption with previous reporting year

Select from:

☑ Higher

(9.3.1.29) Please explain

According to the WWF Water Risk Filter tool, our Puerto Rico facility is located in a region with Medium Physical Basin Risk. The Physical Basin Risk category includes water availability, drought, flooding, water quality, and ecosystem services. Puerto Rico has been affected by natural disasters, including droughts in the mid-2010s and Hurricanes Maria in 2017 and Fiona in 2022, and earthquakes in 2020. These natural disasters have affected, and may continue to affect, public and private properties and Puerto Rico's electric grid and communications networks in the future. Further instability of the electric grid could require us to increase the use of our generators or to use them exclusively. Amgen has taken precautions to limit the impacts of storm events. For example, multiple engineering mitigation measures exist at the Puerto Rico facility to reduce water-related risks, and the site operates a combined heat and power plant and has emergency power generators for continuity of operations during an extreme weather event. The site also has an on-site wastewater treatment plant that treats and reuses water for industrial purposes, reducing reliance on municipal water. Two additional on-site water wells were also constructed to ensure capacity during low water supply periods.

Row 2

(9.3.1.1) Facility reference number

Select from:

☑ Facility 2

(9.3.1.2) Facility name (optional)

Amgen Thousand Oaks

(9.3.1.3) Value chain stage

Select from:

☑ Direct operations

(9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☑ Risks

(9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☑ Yes, withdrawals and discharges

(9.3.1.7) Country/Area & River basin

United States of America

☑ Other, please specify :North Pacific - WWF Water Risk Filter

(9.3.1.8) Latitude

34.192144

(9.3.1.9) Longitude

-118.919522

(9.3.1.10) Located in area with water stress

Select from:

☑ Yes

(9.3.1.13) Total water withdrawals at this facility (megaliters)

885

(9.3.1.14) Comparison of total withdrawals with previous reporting year

Select from:

☑ Higher

(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes

0

(9.3.1.16) Withdrawals from brackish surface water/seawater

0

(9.3.1.17) Withdrawals from groundwater - renewable

0

(9.3.1.18) Withdrawals from groundwater - non-renewable

0

(9.3.1.19) Withdrawals from produced/entrained water

0

(9.3.1.20) Withdrawals from third party sources

885

(9.3.1.21) Total water discharges at this facility (megaliters)

739

(9.3.1.22) Comparison of total discharges with previous reporting year

Select from:

☑ Higher

(9.3.1.23) Discharges to fresh surface water

0

(9.3.1.24) Discharges to brackish surface water/seawater

0

(9.3.1.25) Discharges to groundwater

112

(9.3.1.26) Discharges to third party destinations

627

(9.3.1.27) Total water consumption at this facility (megaliters)

146

(9.3.1.28) Comparison of total consumption with previous reporting year

Select from:

☑ Higher

(9.3.1.29) Please explain

Situation: Amgen operates R&D, manufacturing, commercial and warehouse operations in Thousand Oaks, California, and this location is vulnerable to wildfire risk. Temperature increases and lack of rainfall can exacerbate drought conditions that can extend the wildfire season, increasing the likelihood and severity of a fire event. Task: In 2023, Amgen performed a wide-ranging risk assessment to further our understanding of climate-related physical and transition risks across our value chain under multiple risk scenarios across short-, medium- and long-term timeframes. Action: The 2023 work included an assessment of risk at Amgen's Thousand Oaks facility. Results: Multiple engineering and disaster prevention measures are in place that reduce water reliance, for example improved reverse osmosis technologies, manufacturing process improvement such as clean-in-place (CIP) cycles, and landscape improvements.
[Add row]

(9.3.2) For the facilities in your direct operations referenced in 9.3.1, what proportion of water accounting data has been third party verified?

Water withdrawals – total volumes

(9.3.2.1) % verified

Select from:

☑ 76-100

(9.3.2.2) Verification standard used

Amgen annually engages a third party to conduct an independent assurance of selected environmental data. The statement regarding 2024 data is available on amgen.com at: https://wwwext.amgen.com/responsibility/

Water withdrawals – volume by source

(9.3.2.1) % verified

Select from:

☑ 76-100

(9.3.2.2) Verification standard used

Amgen annually engages a third party to conduct an independent assurance of selected environmental data. The statement regarding 2024 data is available on amgen.com at: https://wwwext.amgen.com/responsibility/

Water withdrawals – quality by standard water quality parameters

(9.3.2.1) % verified

Select from:

☑ 76-100

(9.3.2.2) Verification standard used

Amgen annually engages a third party to conduct an independent assurance of selected environmental data. The statement regarding 2024 data is available on amgen.com at: https://wwwext.amgen.com/responsibility/

Water discharges – total volumes

(9.3.2.1) % verified

Select from:

☑ 76-100

(9.3.2.2) Verification standard used

Amgen annually engages a third party to conduct an independent assurance of selected environmental data. The statement regarding 2024 data is available on amgen.com at: https://wwwext.amgen.com/responsibility/

Water discharges – volume by destination

(9.3.2.1) % verified

Select from:

☑ 76-100

(9.3.2.2) Verification standard used

Amgen annually engages a third party to conduct an independent assurance of selected environmental data. The statement regarding 2024 data is available on amgen.com at: https://wwwext.amgen.com/responsibility/

Water discharges – volume by final treatment level

(9.3.2.1) % verified

Select from:

☑ 76-100

(9.3.2.2) Verification standard used

Amgen annually engages a third party to conduct an independent assurance of selected environmental data. The statement regarding 2024 data is available on amgen.com at: https://wwwext.amgen.com/responsibility/

Water discharges – quality by standard water quality parameters

(9.3.2.1) % verified

Select from:

☑ 76-100

(9.3.2.2) Verification standard used

Amgen annually engages a third party to conduct an independent assurance of selected environmental data. The statement regarding 2024 data is available on amgen.com at: https://wwwext.amgen.com/responsibility/

Water consumption – total volume

(9.3.2.1) % verified

Select from:

☑ 76-100

(9.3.2.2) Verification standard used

Amgen annually engages a third party to conduct an independent assurance of selected environmental data. The statement regarding 2024 data is available on amgen.com at: https://wwwext.amgen.com/responsibility/
[Fixed row]

(9.4) Could any of your facilities reported in 9.3.1 have an impact on a requesting CDP supply chain member?

Select from:

☑ Yes, CDP supply chain members buy goods or services from facilities listed in 9.3.1

(9.4.1) Indicate which of the facilities referenced in 9.3.1 could impact a requesting CDP supply chain member.

Row 1

(9.4.1.1) Facility reference number

Select from:

☑ Facility 1

(9.4.1.2) Facility name

Amgen Manufacturing Limited

(9.4.1.3) Requesting member

Select from:

☑ U.S. General Services Administration - OMB ICR #3090-0319

(9.4.1.4) Description of potential impact on member

Our Amgen Manufacturing Limited facility in Puerto Rico has been identified as having substantive water-related dependencies, impacts, risks, and opportunities. For instance, Puerto Rico has been affected by natural disasters, including droughts in the mid-2010s and Hurricanes Maria in 2017 and Fiona in 2022, as well as earthquakes in 2020. These natural disasters have affected, and may continue to affect, public and private properties. These climate-related risks to our Puerto Rico facility have the potential to impact the operations of our peers with activities in Puerto Rico as well. While water-related climate risks are localized and have the potential to affect such communities, Amgen strives to continually improve our use of water resources within our communities in alignment with our 2027 Environmental Sustainability Plan to reduce water consumption by 40% from a 2019 baseline.

(9.4.1.5) Comment

Row 2

(9.4.1.1) Facility reference number

Select from:

☑ Facility 1

(9.4.1.2) Facility name

Amgen Manufacturing Limited

(9.4.1.3) Requesting member

Select from:

☑ United Health Group Inc

(9.4.1.4) Description of potential impact on member

Our Amgen Manufacturing Limited facility in Puerto Rico has been identified as having substantive water-related dependencies, impacts, risks, and opportunities. For instance, Puerto Rico has been affected by natural disasters, including droughts in the mid-2010s and Hurricanes Maria in 2017 and Fiona in 2022, as well as earthquakes in 2020. These natural disasters have affected, and may continue to affect, public and private properties. These climate-related risks to our Puerto Rico facility have the potential to impact the operations of our peers with activities in Puerto Rico as well. While water-related climate risks are localized and have the potential to affect such communities, Amgen strives to continually improve our use of water resources within our communities in alignment with our 2027 Environmental Sustainability Plan to reduce water consumption by 40% from a 2019 baseline.

(9.4.1.5) Comment

Row 3

(9.4.1.1) Facility reference number

Select from:

☑ Facility 1

(9.4.1.2) Facility name

Amgen Manufacturing Limited

(9.4.1.3) Requesting member

Select from:

☑ Loblaw Companies Limited

(9.4.1.4) Description of potential impact on member

Our Amgen Manufacturing Limited facility in Puerto Rico has been identified as having substantive water-related dependencies, impacts, risks, and opportunities. For instance, Puerto Rico has been affected by natural disasters, including droughts in the mid-2010s and Hurricanes Maria in 2017 and Fiona in 2022, as well as earthquakes in 2020. These natural disasters have affected, and may continue to affect, public and private properties. These climate-related risks to our Puerto Rico facility have the potential to impact the operations of our peers with activities in Puerto Rico as well. While water-related climate risks are localized and have the

potential to affect such communities, Amgen strives to continually improve our use of water resources within our communities in alignment with our 2027 Environmental Sustainability Plan to reduce water consumption by 40% from a 2019 baseline.

(9.4.1.5) Comment

Row 4

(9.4.1.1) Facility reference number

Select from:

☑ Facility 1

(9.4.1.2) Facility name

Amgen Manufacturing Limited

(9.4.1.3) Requesting member

Select from:

☑ Novartis

(9.4.1.4) Description of potential impact on member

Our Amgen Manufacturing Limited facility in Puerto Rico has been identified as having substantive water-related dependencies, impacts, risks, and opportunities. For instance, Puerto Rico has been affected by natural disasters, including droughts in the mid-2010s and Hurricanes Maria in 2017 and Fiona in 2022, as well as earthquakes in 2020. These natural disasters have affected, and may continue to affect, public and private properties. These climate-related risks to our Puerto Rico facility have the potential to impact the operations of our peers with activities in Puerto Rico as well. While water-related climate risks are localized and have the potential to affect such communities, Amgen strives to continually improve our use of water resources within our communities in alignment with our 2027 Environmental Sustainability Plan to reduce water consumption by 40% from a 2019 baseline.

(9.4.1.5) Comment

Row 5

(9.4.1.1) Facility reference number

Select from:

☑ Facility 1

(9.4.1.2) Facility name

Amgen Manufacturing Limited

(9.4.1.3) Requesting member

Select from:

☑ Daiichi Sankyo Co., Ltd.

(9.4.1.4) Description of potential impact on member

Our Amgen Manufacturing Limited facility in Puerto Rico has been identified as having substantive water-related dependencies, impacts, risks, and opportunities. For instance, Puerto Rico has been affected by natural disasters, including droughts in the mid-2010s and Hurricanes Maria in 2017 and Fiona in 2022, as well as earthquakes in 2020. These natural disasters have affected, and may continue to affect, public and private properties. These climate-related risks to our Puerto Rico facility have the potential to impact the operations of our peers with activities in Puerto Rico as well. While water-related climate risks are localized and have the potential to affect such communities, Amgen strives to continually improve our use of water resources within our communities in alignment with our 2027 Environmental Sustainability Plan to reduce water consumption by 40% from a 2019 baseline.

(9.4.1.5) Comment

Row 6

(9.4.1.1) Facility reference number

Select from:

☑ Facility 2

(9.4.1.2) Facility name

Amgen, Thousand Oaks

(9.4.1.3) Requesting member

Select from:

☑ U.S. General Services Administration - OMB ICR #3090-0319

(9.4.1.4) Description of potential impact on member

Amgen operates key R&D, manufacturing, and product warehouse operations at our headquarters in Thousand Oaks, California, a region prone to seasonal wildfire risk. This facility has been identified as having substantive water-related dependencies, impacts, risks, and opportunities. A substantial disruption in our ability to operate our Thousand Oaks manufacturing facility could materially and adversely affect our ability to supply product candidates for our clinical trials, leading to delays in development of our product candidates. Temperature increases and lack of rainfall exacerbate drought conditions that can extend the wildfire season thus increasing likelihood and severity of a fire event. These climate-related risks to our Thousand Oaks facility have the potential to also significantly impact the operations of our peers with activities in California as well.

(9.4.1.5) Comment

Row 7

(9.4.1.1) Facility reference number

Select from:

☑ Facility 2

(9.4.1.2) Facility name

Amgen, Thousand Oaks

(9.4.1.3) Requesting member

Select from:

☑ United Health Group Inc

(9.4.1.4) Description of potential impact on member

Amgen operates key R&D, manufacturing, and product warehouse operations at our headquarters in Thousand Oaks, California, a region prone to seasonal wildfire risk. This facility has been identified as having substantive water-related dependencies, impacts, risks, and opportunities. A substantial disruption in our ability to operate our Thousand Oaks manufacturing facility could materially and adversely affect our ability to supply product candidates for our clinical trials, leading to delays in development of our product candidates. Temperature increases and lack of rainfall exacerbate drought conditions that can extend the wildfire season thus increasing likelihood and severity of a fire event. These climate-related risks to our Thousand Oaks facility have the potential to also significantly impact the operations of our peers with activities in California as well.

(9.4.1.5) Comment

Row 8

(9.4.1.1) Facility reference number

Select from:

☑ Facility 2

(9.4.1.2) Facility name

Amgen, Thousand Oaks

(9.4.1.3) Requesting member

Select from:

☑ Loblaw Companies Limited

(9.4.1.4) Description of potential impact on member

Amgen operates key R&D, manufacturing, and product warehouse operations at our headquarters in Thousand Oaks, California, a region prone to seasonal wildfire risk. This facility has been identified as having substantive water-related dependencies, impacts, risks, and opportunities. A substantial disruption in our ability to operate our Thousand Oaks manufacturing facility could materially and adversely affect our ability to supply product candidates for our clinical trials, leading to delays

in development of our product candidates. Temperature increases and lack of rainfall exacerbate drought conditions that can extend the wildfire season thus increasing likelihood and severity of a fire event. These climate-related risks to our Thousand Oaks facility have the potential to also significantly impact the operations of our peers with activities in California as well.

(9.4.1.5) Comment

Row 11

(9.4.1.1) Facility reference number

Select from:

☑ Facility 1

(9.4.1.2) Facility name

Amgen Manufacturing Limited

(9.4.1.3) Requesting member

Select from:

☑ CVS Health

(9.4.1.4) Description of potential impact on member

Our Amgen Manufacturing Limited facility in Puerto Rico has been identified as having substantive water-related dependencies, impacts, risks, and opportunities. For instance, Puerto Rico has been affected by natural disasters, including droughts in the mid-2010s and Hurricanes Maria in 2017 and Fiona in 2022, as well as earthquakes in 2020. These natural disasters have affected, and may continue to affect, public and private properties. These climate-related risks to our Puerto Rico facility have the potential to impact the operations of our peers with activities in Puerto Rico as well. While water-related climate risks are localized and have the potential to affect such communities, Amgen strives to continually improve our use of water resources within our communities in alignment with our 2027 Environmental Sustainability Plan to reduce water consumption by 40% from a 2019 baseline.

(9.4.1.5) Comment

Row 12

(9.4.1.1) Facility reference number

Select from:

☑ Facility 2

(9.4.1.2) Facility name

Amgen, Thousand Oaks

(9.4.1.3) Requesting member

Select from:

☑ CVS Health

(9.4.1.4) Description of potential impact on member

Amgen operates key R&D, manufacturing, and product warehouse operations at our headquarters in Thousand Oaks, California, a region prone to seasonal wildfire risk. This facility has been identified as having substantive water-related dependencies, impacts, risks, and opportunities. A substantial disruption in our ability to operate our Thousand Oaks manufacturing facility could materially and adversely affect our ability to supply product candidates for our clinical trials, leading to delays in development of our product candidates. Temperature increases and lack of rainfall exacerbate drought conditions that extend the wildfire season thus increasing likelihood and severity of a fire event. These climate-related risks to our Thousand Oaks facility have the potential to also significantly impact the operations of our peers with activities in California as well.

(9.4.1.5) Comment

[Add row]

(9.5) Provide a figure for your organization’s total water withdrawal efficiency.

(9.5.1) Revenue (currency)

33424000000

(9.5.2) Total water withdrawal efficiency

15276051.19

(9.5.3) Anticipated forward trend

In alignment with our 2027 Environmental Sustainability Plan to reduce water consumption by 40% from a 2019 baseline (considering only verified reduction projects), we seek to improve our water withdrawal efficiency with efforts that include implementation of water-efficiency projects, designing innovative new facilities, water treatment and recycling efforts, and other strategic initiatives. As our business expands to reach more patients, we anticipate that our water withdrawals may increase.
[Fixed row]

(9.12) Provide any available water intensity values for your organization's products or services.

	Product name	Comment
Row 1	*Not applicable*	*Not applicable*

[Add row]

(9.13) Do any of your products contain substances classified as hazardous by a regulatory authority?

	Products contain hazardous substances	Comment
	Select from: ☑ No	*No, our products do not contain hazardous products to assure patient safety.*

[Fixed row]

(9.14) Do you classify any of your current products and/or services as low water impact?

(9.14.1) Products and/or services classified as low water impact

Select from:

☑ Yes

(9.14.2) Definition used to classify low water impact

Products from our innovative biotechnology manufacturing facilities in Rhode Island and Singapore use less water to produce the same materials than traditional manufacturing facilities and therefore have a lower water footprint. In 2024, Singapore, reduced water usage by 41% from its 2019 baseline through innovative manufacturing technologies. The technology at these manufacturing facilities is also being incorporated into our new Ohio and North Carolina facilities. These newest facilities remain guided by Amgen Ecovation™, our approach to innovative and sustainable manufacturing. Amgen's Environmental Sustainability program includes goals, strategies, and metrics to measure and track our progress in mitigating our overall environmental impact in capital projects.

(9.14.4) Please explain

Our Singapore and Rhode Island manufacturing facilities were designed and built to minimize our environmental footprint. Our newest facilities, in Ohio and North Carolina, remain guided by Amgen Ecovation™, our approach to innovative and sustainable manufacturing which we embed into the upfront design, development and execution of all new laboratory, manufacturing, and administrative buildings. This approach underscores what is today, and has always been, distinctive about biomanufacturing at Amgen: our focus on highly innovative, efficient, safe, and environmentally sustainable operations – all in service of benefiting patients. Amgen 's Environmental Sustainability program includes goals, strategies, and metrics to measure and track our progress in mitigating our overall environmental impact in capital projects. We consider products from our innovative biotechnology manufacturing facilities to have lower water impacts than traditional facilities.
[Fixed row]

(9.15) Do you have any water-related targets?

Select from:
☑ Yes

(9.15.1) Indicate whether you have targets relating to water pollution, water withdrawals, WASH, or other water-related categories.

	Target set in this category	Please explain
Water pollution	*Select from:* ☑ No, and we do not plan to within the next two years	*Amgen's wastewater is generally consistent with municipal wastewater due to segregation and proper disposal of unwanted constituents.*
Water withdrawals	*Select from:* ☑ Yes	*Rich text input [must be under 1000 characters]*
Water, Sanitation, and Hygiene (WASH) services	*Select from:* ☑ No, and we do not plan to within the next two years	*Amgen designs and operates its facilities to meet or exceed local wastewater discharge requirements.*
Other	*Select from:* ☑ No, and we do not plan to within the next two years	*Not relevant.*

[Fixed row]

(9.15.2) Provide details of your water-related targets and the progress made.

Row 1

(9.15.2.1) Target reference number

Select from:

☑ Target 1

(9.15.2.2) Target coverage

Select from:

☑ Organization-wide (direct operations only)

(9.15.2.3) Category of target & Quantitative metric

Water withdrawals

☑ Reduction in total water withdrawals

(9.15.2.4) Date target was set

01/01/2019

(9.15.2.5) End date of base year

12/31/2019

(9.15.2.6) Base year figure

2146000

(9.15.2.7) End date of target year

12/31/2027

(9.15.2.8) Target year figure

1287500